...
search icon
imab-img

I-Mab, Common Stock

IMAB

NMQ

$1.03

-$0.05

(-4.63%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$83.95M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
380.01K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.08
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.84 L
$2.08 H
$1.03

About I-Mab, Common Stock

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameIMABSectorS&P500
1-Week Return-5.5%3.54%-0.58%
1-Month Return17.05%7.51%1.89%
3-Month Return-13.45%-0.85%3.24%
6-Month Return-24.26%-1.67%10.09%
1-Year Return-47.98%5.2%22.09%
3-Year Return-95.38%13.08%35.68%
5-Year Return-92.47%44.4%83.47%
10-Year Return-91.76%111.45%200.41%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue30.00M1.54B88.03M(221.56M)27.64M[{"date":"2019-12-31","value":1.94,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":5.71,"profit":true},{"date":"2022-12-31","value":-14.36,"profit":false},{"date":"2023-12-31","value":1.79,"profit":true}]
Cost of Revenue--46.43M27.24M-[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":58.66,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Profit30.00M1.54B41.59M(248.80M)27.64M[{"date":"2019-12-31","value":1.94,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":2.7,"profit":true},{"date":"2022-12-31","value":-16.13,"profit":false},{"date":"2023-12-31","value":1.79,"profit":true}]
Gross Margin100.00%100.00%47.25%112.29%100.00%[{"date":"2019-12-31","value":89.05,"profit":true},{"date":"2020-12-31","value":89.05,"profit":true},{"date":"2021-12-31","value":42.08,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":89.05,"profit":true}]
Operating Expenses1.49B1.08B2.40B2.28B201.20M[{"date":"2019-12-31","value":62.33,"profit":true},{"date":"2020-12-31","value":45.16,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.29,"profit":true},{"date":"2023-12-31","value":8.39,"profit":true}]
Operating Income(1.46B)155.57M(2.07B)(1.97B)(1.24B)[{"date":"2019-12-31","value":-941.68,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-1331.43,"profit":false},{"date":"2022-12-31","value":-1265.97,"profit":false},{"date":"2023-12-31","value":-794.51,"profit":false}]
Total Non-Operating Income/Expense40.60M350.85M(242.06M)(510.25M)(178.65M)[{"date":"2019-12-31","value":11.57,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-68.99,"profit":false},{"date":"2022-12-31","value":-145.43,"profit":false},{"date":"2023-12-31","value":-50.92,"profit":false}]
Pre-Tax Income(1.45B)483.15M(2.33B)(2.51B)(1.47B)[{"date":"2019-12-31","value":-300.52,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-483.23,"profit":false},{"date":"2022-12-31","value":-518.81,"profit":false},{"date":"2023-12-31","value":-303.36,"profit":false}]
Income Taxes2.89M12.23M3.15M697.00K(1.26B)[{"date":"2019-12-31","value":23.65,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":25.79,"profit":true},{"date":"2022-12-31","value":5.7,"profit":true},{"date":"2023-12-31","value":-10292.91,"profit":false}]
Income After Taxes(1.45B)470.92M(2.34B)(2.51B)(206.77M)[{"date":"2019-12-31","value":-308.94,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-496.45,"profit":false},{"date":"2022-12-31","value":-532.44,"profit":false},{"date":"2023-12-31","value":-43.91,"profit":false}]
Income From Continuous Operations(1.45B)470.92M(2.33B)(2.41B)(1.47B)[{"date":"2019-12-31","value":-308.33,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-495.11,"profit":false},{"date":"2022-12-31","value":-512.16,"profit":false},{"date":"2023-12-31","value":-311.24,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(1.45B)470.92M(2.33B)(2.51B)(1.47B)[{"date":"2019-12-31","value":-308.94,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-495.11,"profit":false},{"date":"2022-12-31","value":-532.44,"profit":false},{"date":"2023-12-31","value":-311.24,"profit":false}]
EPS (Diluted)-1.02(1.59)(2.92)-[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-155.66,"profit":false},{"date":"2022-12-31","value":-285.51,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

IMAB
Cash Ratio 15.66
Current Ratio 15.99

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

IMAB
ROA (LTM) -29.25%
ROE (LTM) -71.72%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

IMAB
Debt Ratio Lower is generally better. Negative is bad. 0.06
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.94

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

IMAB
Trailing PE NM
Forward PE NM
P/S (TTM) 24.04
P/B 0.40
EV/R 0.99
EV/Ebitda 0.14

FAQs

What is I-Mab share price today?

I-Mab (IMAB) share price today is $1.03

Can Indians buy I-Mab shares?

Yes, Indians can buy shares of I-Mab (IMAB) on Vested. To buy I-Mab from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IMAB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of I-Mab be purchased?

Yes, you can purchase fractional shares of I-Mab (IMAB) via the Vested app. You can start investing in I-Mab (IMAB) with a minimum investment of $1.

How to invest in I-Mab shares from India?

You can invest in shares of I-Mab (IMAB) via Vested in three simple steps:

  • Click on Sign Up or Invest in IMAB stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in I-Mab shares
What is I-Mab 52-week high and low stock price?

The 52-week high price of I-Mab (IMAB) is $2.08. The 52-week low price of I-Mab (IMAB) is $0.84.

What is I-Mab price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of I-Mab (IMAB) is 0.40

What is the Market Cap of I-Mab?

The market capitalization of I-Mab (IMAB) is $83.95M

What is I-Mab’s stock symbol?

The stock symbol (or ticker) of I-Mab is IMAB

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top